Arnuity Ellipta Approval History
- FDA approved: Yes (First approved August 20th, 2014)
- Brand name: Arnuity Ellipta
- Generic name: fluticasone furoate
- Dosage form: Inhalation Powder
- Company: GlaxoSmithKline
- Treatment for: Asthma, Asthma, Maintenance
Arnuity Ellipta (fluticasone furoate inhalation powder) is a once-daily inhaled corticosteroid for the maintenance treatment of asthma.
Development History and FDA Approval Process for Arnuity Ellipta
|May 24, 2018||GSK Receives FDA Approval of Arnuity Ellipta for Asthma in Children From 5 Years of Age|
|Aug 21, 2014||FDA Approves Arnuity Ellipta (fluticasone furoate) for the Treatment of Asthma|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.